|
US3498989A
(en)
|
1969-04-16 |
1970-03-03 |
American Home Prod |
Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
|
|
US3870715A
(en)
|
1972-03-09 |
1975-03-11 |
Nikolaus R Hansl |
Substituted amino ethyl meta benzoic acid esters
|
|
US4041174A
(en)
|
1974-08-16 |
1977-08-09 |
Rom-Amer Pharmaceuticals, Ltd. |
Method of treating depression
|
|
US5204356A
(en)
|
1985-07-24 |
1993-04-20 |
Glaxo Group Limited |
Treatment of anxiety
|
|
US6150354A
(en)
|
1987-01-15 |
2000-11-21 |
Bonnie Davis |
Compounds for the treatment of Alzheimer's disease
|
|
GB8819494D0
(en)
|
1988-08-16 |
1988-09-21 |
Ucb Sa |
Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
|
|
DE69232909D1
(de)
*
|
1991-02-22 |
2003-03-06 |
Howard K Shapiro |
Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe
|
|
US6746678B1
(en)
|
1991-02-22 |
2004-06-08 |
Howard K. Shapiro |
Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
|
|
FR2700117B1
(fr)
|
1993-01-07 |
1995-02-03 |
Rhone Poulenc Rorer Sa |
Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
|
|
DE4340273A1
(de)
|
1993-11-26 |
1995-06-01 |
Karla Dr Lehmann |
Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
|
|
US5453425A
(en)
|
1994-07-11 |
1995-09-26 |
Janssen Pharmaceutica N.V. |
Risperidone oral formulation
|
|
WO2001041707A2
(en)
|
1999-12-08 |
2001-06-14 |
Vanderbilt University |
Modulation of in vivo glutamine and glycine levels in the treatment of autism
|
|
CA2419314C
(en)
|
2000-08-14 |
2006-07-11 |
Teva Pharmaceutical Industries Ltd. |
Preparation of risperidone
|
|
AU2002247939B2
(en)
|
2001-01-16 |
2007-01-25 |
Serono Genetics Institute S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
|
US20030185754A1
(en)
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
|
US20070053976A1
(en)
|
2002-05-17 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
Novel combination of drugs as antidepressant
|
|
US7053122B2
(en)
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
AU2003274353B2
(en)
|
2002-10-24 |
2007-04-05 |
Merz Pharma Gmbh & Co. Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
|
WO2004065348A1
(en)
|
2003-01-23 |
2004-08-05 |
Pfizer Products Inc. |
Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
|
|
WO2005000205A2
(en)
|
2003-06-02 |
2005-01-06 |
Samaritan Pharmaceuticals, Inc. |
Methods and compositions for modulating serum cortisol levels
|
|
NZ548213A
(en)
|
2003-12-29 |
2010-05-28 |
Sepracor Inc |
Benzo[d]isoxazol-3-ol DAAO inhibitors
|
|
EP1709053B1
(en)
|
2004-01-27 |
2011-04-06 |
Synthon B.V. |
Stable salts of olanzapine
|
|
EP1742624B1
(en)
|
2004-02-18 |
2010-01-06 |
Sepracor, Inc. |
Dopamine-agonist combination therapy with sedatives for improving sleep quality
|
|
KR20070009671A
(ko)
|
2004-05-06 |
2007-01-18 |
사이덱스 인크 |
세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제
|
|
US7803786B2
(en)
|
2004-06-17 |
2010-09-28 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions and related methods of use
|
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
|
CA2505808A1
(en)
*
|
2005-05-02 |
2006-11-02 |
Julie Danielle Globus |
Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
|
|
WO2006129160A2
(en)
|
2005-06-01 |
2006-12-07 |
Aurobindo Pharma Limited |
Stable aqueous oral solution of risperidone
|
|
US20110045065A1
(en)
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
US7811604B1
(en)
|
2005-11-14 |
2010-10-12 |
Barr Laboratories, Inc. |
Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
|
|
GB0603181D0
(en)
|
2006-02-17 |
2006-03-29 |
Merck Sharp & Dohme |
Treatment of neurodegenerative and psychiatric diseases
|
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
|
US20080070984A1
(en)
|
2006-09-15 |
2008-03-20 |
Tran Pierre V |
Compositions and Methods of Treating Schizophrenia
|
|
US8071143B2
(en)
|
2008-04-02 |
2011-12-06 |
Brandeis University |
Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
|
|
US8541435B2
(en)
*
|
2008-07-11 |
2013-09-24 |
Uday Saxena |
Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
|
|
US20130338199A1
(en)
*
|
2008-07-11 |
2013-12-19 |
Uday Saxena |
Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
|
|
GB0813709D0
(en)
|
2008-07-26 |
2008-09-03 |
Univ Dundee |
Method and product
|
|
JP2010106001A
(ja)
*
|
2008-10-31 |
2010-05-13 |
Theravalues Corp |
Ｐｐａｒ活性化剤
|
|
MX374638B
(es)
|
2009-01-20 |
2025-03-06 |
Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct |
Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.
|
|
MX341072B
(es)
*
|
2010-07-23 |
2016-08-05 |
Grünenthal Gmbh * |
Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
|
|
US10130708B2
(en)
|
2011-03-24 |
2018-11-20 |
University Of South Florida |
Lithium cocrystal compositions
|
|
US9035044B2
(en)
*
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
US9120766B2
(en)
*
|
2011-10-21 |
2015-09-01 |
Amri Ssci, Llc |
Methods of making cocrystals
|
|
PL2986618T3
(pl)
*
|
2013-04-19 |
2022-07-18 |
University Of South Florida |
Organiczne anionowe jonowe związki kokrystaliczne i kompozycje litu
|
|
WO2014178040A1
(en)
|
2013-04-29 |
2014-11-06 |
Mapi Pharma Ltd. |
Co-crystals of dapagliflozin
|
|
EP3079675B1
(en)
*
|
2013-12-13 |
2020-02-12 |
CONARIS research institute AG |
A pharmaceutical composition containing nicotinic acid and/or nicotinamide for use in beneficially influencing blood lipid levels by modifying the intestinal microbiota
|
|
KR20160029837A
(ko)
*
|
2014-03-24 |
2016-03-15 |
가오슝 창 궁 메모리얼 하스피털 |
치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도
|
|
CN103992320A
(zh)
|
2014-05-26 |
2014-08-20 |
南京工业大学 |
一种混悬结晶制备药物共晶的方法
|
|
EP3220906B1
(en)
*
|
2014-11-19 |
2022-03-02 |
Rush University Medical Center |
Compositions and methods for treating lysosomal disorders
|
|
RU2582962C1
(ru)
*
|
2014-12-23 |
2016-04-27 |
Ольга Алексеевна Громова |
Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
|
|
WO2017215593A1
(en)
|
2016-06-13 |
2017-12-21 |
Syneurx International (Taiwan) Corp. |
Co-crystals of sodium benzoate and uses thereof
|